Use of the polymerase-chain reaction (PCR) for early evaluation of etiological treatment in young adults chronically infected with Trypanosoma cruzi by Lacunza, Carlos Diego et al.
Vol. 35 (3): 217-222. set.-dez. 2006 217
USE OF THE POLYMERASE CHAIN REACTION (PCR)
FOR EARLY EVALUATION 
OF ETIOLOGICAL TREATMENT IN YOUNG ADULTS, 
CHRONICALLY INFECTED WITH Trypanosoma cruzi
ARTIGO ORIGINAL
1 Instituto de Patología Experimental-CONICET, Facultad de Ciencias de la Salud, Universidad 
Nacional de Salta, Argentina.
2 Dirección de Sanidad Universitaria, Universidad Nacional de Salta, Argentina.
Endereço para correspondência: Dr. Carlos D. Lacunza, Mitre 664 (4400) Salta, Argentina. E mail: 
diegolacunza@yahoo.com.ar
Recebido para publicação em: 29/9/2006. Revisto em: 2/12/2006. Aceito em: 26/12/2006.
Carlos Diego Lacunza, 1 Olga Sánchez Negrete, 1 María Celia Mora,1 Alejandro 
Uncos, 1 María Asunción Segura, 1 Néstor Del Castillo, 2 María Isabel Garayzabal, 2 
and Miguel Ángel Basombrío 1
ABSTRACT
Fourteen patients (age limits: 18-30) chronically infected with Trypanosoma cruzi and presenting 
positive blood PCR reactions, were submitted to etiological treatment with benznidazole, in Salta, 
Argentina. A control group of ﬁve patients of the same age and positive by PCR did not receive 
treatment. Post-treatment follow-up was performed with PCR and conventional serology. PCR 
became negative in 12/14 (85.7%) of the treated patients after six months follow up, compared to 1/5 
(20%) in the control group (p = 0.01). All patients remained serologically positive after treatment. 
The reduction of PCR signals of infection after treatment may become an early evidence of cure in 
chronically infected young adult patients.
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INTRODUCTION
Trypanosoma cruzi infects around 18 million persons in an endemic 
area from northern Mexico to southern Argentina (15). The population at risk of 
infection is estimated at 40 millions (15), and Chagas disease is one of the major 
causes of morbi-mortality in the region. Additionally, this disease has extended, due 
to migrations, to countries such as Spain (6) and the USA (7).
The etiological treatment of chronically infected patients has been 
recommended by the World Health Organization (10). Brazil (8) and Argentina (9) 
treatment guidelines also recommend treatment for such patients, stating that the 
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decision should be taken by each patient and his/her physician. Conventional serologic 
(Enzyme Linked Immunosorbent Assay - ELISA, Indirect Hemagglutination - IHA) 
and parasitologic (Hemoculture, Xenodiagnosis) methods are recommended for the 
control of therapeutic efﬁcacy. However, in the chronic phase, conventional reactions 
only become negative years after treatment (1, 10), and conventional parasitologic 
methods have low sensitivity (4). The Polymerase Chain Reaction (PCR), 
detecting Trypanosoma cruzi kDNA (13), showed higher diagnostic sensitivity than 
conventional methods in chronic Chagas disease patients (14).
In this work, we explored the usefulness of PCR as a tool for early 
evaluation of the efﬁcacy of etiologic treatment in young adults infected by T. cruzi. 
Treatment was also controlled with conventional serology (IHA, ELISA).
MATERIALS AND METHODS
Subjects
Ninety-one patients were interviewed, age ranged from 18 to 30 years old, 
and they had two positive serological tests (ELISA and IHA). The PCR test was 
applied to all of them. The reaction was positive in 36/91 (65.5%). Treatment was 
initiated in 18 patients and 14 completed the whole treatment course. The control 
group was composed of ﬁve patients who rejected treatment or received it after this 
study. Out of 19 patients thirteen were women. All lived in Salta city, Argentina, 
an area with no vectorial transmission, and signed an informed consent. Exclusion 
criteria were: previous treatment for T. cruzi, pregnancy, liver or kidney disease, 
low leukocyte or platelet counts, alcoholism, severe pathology associated to Chagas 
disease and breast-feeding. The project was approved by the Bioethics Commission 
of the Faculty of Medical Sciences of the University of Rosario, Argentina, and of 
the Faculty of Health Sciences of the University of Salta, Argentina.
Treatment
Two groups were studied: the treated group (TG), included 14 patients (age 
range 23.6 ± 3.5 years), which received benznidazole at 5 mg/kg/day for 60 days, by 
oral route. The control group (CG), included 5 patients (age range 26.6 ± 4.9 years), 
which did not receive treatment. The follow-up was of 6 months post-treatment for 
TG and from 2 weeks to 6 months for CG.
Serology
After separating the serum, IHA and ELISA tests were done, using Wiener 
Laboratory kits (Argentina) and following the recommended procedures and cut-off 
points (1/16 dilution for IHA and 0.22 absorbance for ELISA).
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The procedure used by Britto et al. (3) with minor modiﬁcations was used. 
Blood (5 mL) was diluted 1:1 in 6 M-Guanidine EDTA 0.2 M buffer. The sample 
was heated at 100º C 10 minutes. DNA was extracted in minipreps using 100 µl 
sample aliquots, using phenol-chlorophorm-isoamilic alcohol and sodium acetate-
ethanol precipitation. Ampliﬁcation mixtures included primers 121 (5’-AAA TAA 
TGT ACG GGT GAG ATG CAT GA-3’) and 122 (5’-GGT TCG ATT GGG GTT 
GGT GTA ATA TA-3’). Ampliﬁcation was carried out in a thermal cycler (M. J. 
Research, Watertown, Masssachusetts, USA) with the following cycle sequence: 
cycle 1(x2) 1 min at 98º C and 2 min at 64º C; cycle 2 (x33): 1 min at 94 ºC and 
2 min at 64º C; cycle 3 (x1): 1 min at 72º C and 2 min at 25º C. Ampliﬁed products 
were electrophoresed in 0.2 % agarose minigels, stained with ethidium bromide and 
revealed with ultraviolet light. Positive samples displayed a 330 bp band. Because 
cross-contamination or PCR artifacts are a constant risk, a maximum of 5 samples 
was processed, together with a negative and a positive control, per extraction 
session. PCR mixtures and DNA extraction were performed in separate chambers. 
All reagents were prepared in aliquots, using exclusive pipettes and ﬁlter tips. 
Amplicons were electrophoresed in a separate room.
Statistical analysis
The signiﬁcance of differences between proportions was calculated with 
the Fisher’s exact test.
RESULTS
The main outcomes of ELISA, IHA, and PCR for each patient are shown 
in Tables 1 and 2. PCR became negative in 12/14 (85.7%) TG patients at month 
6 post-treatment, and in 1/5 (20%) CG patients (p = 0.01). All patients remained 
serologically positive after treatment (TG), or in the follow-up of the CG.
Seven of 14 (50%) patients in the TG presented adverse effects of 
benznidazole. These were: allergic dermatitis (4/7; 57.2%), peripheral polyneuritis 
(2/7; 28.6%), and asthenia (1/7; 14.3%). Nevertheless, treatment could be completed 
in all patients, by either diminishing temporarily the dose or by symptomatic 
medication. In two cases, adverse effects disappeared spontaneously after the ﬁrst 
days of treatment. 
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Table 1. Results of serological tests and PCR before/after treatment with 
benznidazole of young adults, infected with Trypanosoma cruzi, Salta, 
Argentina
Pt
Before treatment After treatment
IHA ELISA PCR IHA ELISA PCR
1 1/1024 pos pos 1/1024 pos neg
2 1/32 pos pos 1/16 pos neg
3 1/256 pos pos ND ND neg
4 1/512 pos pos 1/128 pos neg
5 1/64 pos pos 1/256 pos pos
6 1/256 pos pos 1/32 pos neg
7 1/512 pos pos 1/256 pos neg
8 1/1024 pos pos 1/512 pos neg
9 1/1024 pos pos 1/512 pos neg
10 1/1024 pos pos 1/512 pos pos
11 1/1024 pos pos 1/1024 pos neg
12 1/64 pos pos 1/512 pos neg
13 1/1024 pos pos 1/512 pos neg
14 1/32 pos pos 1/64 pos neg
Pt: patients; IHA: Indirect Hemagglutination; ELISA: Enzime Linked Immunosorbent Assay; 
pos: positive;  neg: negative; ND: not done.
Table 2. Results of serological tests and PCR of a group of non-treated, 
Trypanosoma cruzi infected, young adults from Salta, Argentina
Pt
Beginning Follow-up
IHA ELISA PCR IHA ELISA PCR
A 1/64 pos pos ND ND pos
B 1/128 pos pos 1/256 pos pos
C 1/64 pos pos ND ND neg
D 1/16 pos pos ND ND pos
E 1/128 pos pos ND ND pos
Pt: patients; pos: positive; neg: negative; ND: not done. 
DISCUSSION
The criterion of cure for Chagas disease is still the negativization of 
conventional serologic and parasitologic tests (5), even though there is not much 
experience using this criterion in chronically infected adults. During this stage of 
the disease, conventional parasitologic tests display low sensitivity and serological 
reactions become negative very late, even in cases of successful treatment (1, 10). 
PCR could overcome both difﬁculties: it could provide results on the efﬁcacy of 
treatment with higher sensitivity than conventional parasitological tests, and earlier 
in time than serological tests.
Vol. 35 (3): 217-222. set.-dez. 2006 221
In this work, a signiﬁcant negativization of PCR was demonstrated in the 
TG. Although these results are promising for monitoring treatment, the relatively 
low sensitivity of PCR should be considered. 65.5% of chronically infected patients 
were positive by PCR. Similar results were observed by other authors (11). A 
negative result after treatment therefore does not indicate cure, although it could 
provide a supporting evidence of cure.
Only two patients presented a positive PCR after treatment. The 
possibilities of contamination and lack of treatment compliance were reasonably 
discarded. Therefore, these results could indicate failure to therapy. This fact 
has been shown in other studies (2), and could be due to infection with resistant 
parasite strains (12).
An important proportion of adverse effects of benznidazole was 
observed. However, most of them were mild or could be resolved with simple 
clinical indications.
To evaluate the effectiveness of PCR as method for assessing therapy in 
chronically infected adults, its sensitivity should be increased and patients should be 
followed-up for longer periods.
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RESUMO
Uso da Reação em Cadeia da Polimerase para a avaliação precoce do tratamento 
etiológico em adultos jovens infectados crônicos por Trypanosoma cruzi
Foi realizado o tratamento etiológico com benznidazol, no Estado de Salta, 
Argentina, em 14 pacientes infetados crônicos por Trypanosoma cruzi, de 18 a 
30 anos de idade, com Reação em Cadeia da Polimerase (PCR) positiva. Um 
grupo controle de cinco pacientes, da mesma idade, também com PCR positiva, 
não recebeu tratamento. O seguimento após tratamento foi realizado com PCR e 
sorología convencional. Após 6 meses de tratamento foi observada negativização 
da PCR de 14/16 (85,7%) nos pacientes tratados versus 20% no grupo controle (p 
= 0,001). A sorologia foi positiva em todos os pacientes depois do tratamento. Os 
resultados da PCR pós-tratamento, podem ser um indício de cura no tratamento de 
infectados chagásicos crônicos, adultos jovens.
DESCRITORES: Doença de Chagas. Tratamento etiologico. Reação em Cadeia da 
Polimerase.
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